Sionna Therapeutics, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Sionna Therapeutics is a clinical-stage biopharmaceutical company developing therapies for cystic fibrosis, focused on correcting the underlying defect in the CFTR protein by targeting its nucleotide-binding domain 1 (NBD1).
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.Insider | Sell | $21.58M | 3,415,011at $6.32 | Sep 17, 2026 |
| RA CAPITAL MANAGEMENT, L.P.Insider | Sell | $252K | 33,800at $7.46 | Sep 17, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable SION activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.